KSQ Therapeutics
Focus: KSQ Therapeutics is a CRISPR-based drug discovery company focused on gene therapy for advanced solid tumors, operating as a small biotech with 1-50 employees.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$350M
Open Jobs
0
About KSQ Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow KSQ Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Cyclophosphamide
Select Advanced Solid TumorsClinical Trials (1)
NCT06598371A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2Help build intelligence for KSQ Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.